Update on psychedelic treatments for depression - David Erritzoe

Psychedelic therapy is experiencing significant advancements in treating depression, with research focusing on psilocybin-assisted therapy and its mechanisms. Clinical studies show sustained antidepressant effects and reduced rumination, highlighting the role of therapeutic support and emotional breakthroughs in achieving positive outcomes. Comparisons between psilocybin and SSRIs reveal distinct mechanisms of action, where psilocybin provides rapid-onset improvement and significant reductions in depressive symptoms. While research on microdosing is ongoing, evidence remains inconclusive regarding its superiority beyond placebo effects. Rigorous investigations, including longitudinal studies and data on medication discontinuation, are crucial for understanding the therapeutic benefits of various psychedelic compounds. Continued exploration of these substances, including DMT and novel interventions, promises deeper insights into their clinical potential for mood disorders.